PATENT CLAIM ANALYSIS

Application Number: 15746838
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "365000"]

Abstract:
The present invention includes novel aminothiazole compounds useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.

Claim (Index 2):
The compound of  claim 1 , wherein the compound of formula (I) is a compound of the formula selected from the group consisting of formula (II)-formula (XVIII): including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (II):\n R 1a , R 1b , R 2a , R 2b , R 2c , R 4 , R 5 , and n are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (III):\n R 1a , R 1b , R 2a , R 2b , R 2c , R 4 , and R 5  are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (IV):\n R 1a , R 1b , R 2a , R 2b , R 2c , R 4 , and R 5  are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (V):\n R 1a , R 1b , R 2a , R 2b , R 2c , R 4 , and R 5  are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (VI):\n R 1a , R 1b , R 2a , R 2b , R 2c , R 4 , and R 5  are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (VII):\n R 2a , R 2b , R 2c , R 3a , R 3b , R 4 , and R 5  are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (VIII):\n R 2a , R 2b , R 2c , R 4 , and R 5  are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (IX):\n R 2a , R 2b , R 2c , R 4 , and R 5  are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (X):\n R 1a , R 1b , R 2a , R 2b , R 2c , R 5 , X 1 , and n are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (XI):\n R 1a , R 1b , R 2a , R 2b , R 2c , R 5 , R 7 , and n are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (XII):\n R 1a , R 1b , R 2a , R 2b , R 2c , R 5 , R 6a , R 6b , R 10a , R 10b , R 10c , R 10d , R 10e  and n are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (XIII):\n R 1a , R 1b , R 2a , R 2b , R 2c , R 5 , R 9 , n, y, and z are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (XIV):\n R 1a , R 1b , R 2a , R 2b , R 2c , R 5 , R 9 , n, and z are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (XV):\n R 1a , R 1b , R 2a , R 2b , R 2c , R 5 , R 9 , and n are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (XVI):\n R 1a , R 1b , R 2a , R 2b , R 2c , R 5 , R 9 , n, and z are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (XVII):\n R 1a , R 1b , R 2a , R 2b , R 2c , R 5 , R 9 , and n are as defined in formula (I); \n including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof; wherein in formula (XVIII):\n R 1a , R 1b , R 2a , R 2b , R 2c , R 5 , R 9 , n, and y are as defined in formula (I).

Metadata:
- Claim Count in Document: 1.0
- Percentile: 86.0
- Lexical Diversity: 1.82759
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15873293', '13863089', '15036743', '15130893', '15549152']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8311384387997462
- 35 USC 102 Novelty (BERT): 0.5173440630088411
- Combined Prediction Score: 0.7997590012206558
- Mean Citation Score: 294.155088
- Max Citation Score: 331.12177
- Similarity Product: 290.01346342301133

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test